Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 8
- Registration Number
- NCT02765256
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 64
- Registration Number
- NCT02743234
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus C, Denmark
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 2
- Registration Number
- NCT02732327
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Interventional Bioremediation of Microbiota in Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT02730962
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
- Conditions
- Interventions
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 144
- Registration Number
- NCT02692651
- Locations
- 🇺🇸
St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Queen Elizabeth II Health Sciences Centre
- Target Recruit Count
- 50
- Registration Number
- NCT02686645
Optimal Treatment for Recurrent Clostridium Difficile
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 308
- Registration Number
- NCT02667418
- Locations
- 🇺🇸
Southern Arizona VA Health Care System, Tucson, AZ, Tucson, Arizona, United States
🇺🇸VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States
🇺🇸Asheville VA Medical Center, Asheville, NC, Asheville, North Carolina, United States
Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution
- Conditions
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Drexel University
- Target Recruit Count
- 10
- Registration Number
- NCT02663596
- Locations
- 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Sharp HealthCare
- Target Recruit Count
- 40
- Registration Number
- NCT02660346
- Locations
- 🇺🇸
Sharp Grossmont Hospital, La Mesa, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
Intrawound Vancomycin Powder in Spinal Fusion Surgery
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Orthopedic Hospital Vienna Speising
- Target Recruit Count
- 308
- Registration Number
- NCT02631408
- Locations
- 🇦🇹
Orhopedic Hospital Speising, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.